IN8bio announces preclinical data from its INB-619 program

IN8bio (INAB) announced new preclinical data from its INB-619 program at the 2025 American Society of Gene & Cell Therapy, ASGCT, Annual Meeting. The data shows that INB-619 successfully eliminated disease-causing B cells in blood samples from patients with active Systemic Lupus Erythematosus. Highlights from the Preclinical Data: INB-619 demonstrated complete, targeted depletion of B cells in lupus patient-derived samples. IN8bio’s gammadelta TCE successfully expands both Vdelta1+ and Vdelta2+ subtypes of gammadelta T cells, which are critical for targeting both circulating and tissue-resident B cells to potentially achieve deeper B cell depletion. Unlike conventional CD3-based TCEs, INB-619 did not trigger significant release of inflammatory cytokines such as IL-6, which are commonly associated with serious toxicities, including CRS. The study reinforces the potential of gammadelta T cell engagers as a safer, more precise immunotherapy platform for autoimmune diseases.